258 related articles for article (PubMed ID: 10950939)
1. Detailed mapping of methylcytosine positions at the CpG island surrounding the Pa promoter at the bcr-abl locus in CML patients and in two cell lines, K562 and BV173.
Fajkusová L; Fajkus J; Polácková K; Fulnecek J; Dvoráková D; Krahulcová E
Blood Cells Mol Dis; 2000 Jun; 26(3):193-204. PubMed ID: 10950939
[TBL] [Abstract][Full Text] [Related]
2. ABL1 promoter methylation can exist independently of BCR-ABL transcription in chronic myeloid leukemia hematopoietic progenitors.
Sun B; Jiang G; Zaydan MA; La Russa VF; Safah H; Ehrlich M
Cancer Res; 2001 Sep; 61(18):6931-7. PubMed ID: 11559572
[TBL] [Abstract][Full Text] [Related]
3. Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia.
Zion M; Ben-Yehuda D; Avraham A; Cohen O; Wetzler M; Melloul D; Ben-Neriah Y
Proc Natl Acad Sci U S A; 1994 Oct; 91(22):10722-6. PubMed ID: 7938018
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional activation of human LIM-HOX gene, hLH-2, in chronic myelogenous leukemia is due to a cis-acting effect of Bcr-Abl.
Wu HK; Minden MD
Biochem Biophys Res Commun; 1997 Apr; 233(3):806-12. PubMed ID: 9168938
[TBL] [Abstract][Full Text] [Related]
5. The molecular biology of chronic myeloid leukaemia.
Melo JV
Leukemia; 1996 May; 10(5):751-6. PubMed ID: 8656667
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional activation of human LIM-HOX gene hLH-2 in chronic myelogenous leukemia is due to a cis-acting effect of Bcr-Abl.
Wu HK; Minden MD
Biochem Biophys Res Commun; 1997 May; 234(3):742-7. PubMed ID: 9175786
[TBL] [Abstract][Full Text] [Related]
7. A study on the incidence of ABL gene deletion on derivative chromosome 9 in chronic myelogenous leukemia by interphase fluorescence in situ hybridization and its association with disease progression.
Lee DS; Lee YS; Yun YS; Kim YR; Jeong SS; Lee YK; She CJ; Yoon SS; Shin HR; Kim Y; Cho HI
Genes Chromosomes Cancer; 2003 Jul; 37(3):291-9. PubMed ID: 12759927
[TBL] [Abstract][Full Text] [Related]
8. Integration of amplified BCR/ABL fusion genes into the short arm of chromosome 17 as a novel mechanism of disease progression in chronic myeloid leukemia.
Metzke-Heidemann S; Harder L; Gesk S; Schoch R; Jenisch S; Grote W; Siebert R; Schlegelberger B
Genes Chromosomes Cancer; 2001 May; 31(1):10-4. PubMed ID: 11284030
[TBL] [Abstract][Full Text] [Related]
9. Molecular insights into the Philadelphia translocation.
Heisterkamp N; Groffen J
Hematol Pathol; 1991; 5(1):1-10. PubMed ID: 2050600
[TBL] [Abstract][Full Text] [Related]
10. Heterogenic molecular basis for loss of ABL1-BCR transcription: deletions in der(9)t(9;22) and variants of standard t(9;22) in BCR-ABL1-positive chronic myeloid leukemia.
Loncarevic IF; Römer J; Starke H; Heller A; Bleck C; Ziegler M; Fiedler W; Liehr T; Clement JH; Claussen U
Genes Chromosomes Cancer; 2002 Jun; 34(2):193-200. PubMed ID: 11979553
[TBL] [Abstract][Full Text] [Related]
11. [Molecular analysis of transformation into blast crisis in chronic myelogenous leukemia].
Okabe M
Hokkaido Igaku Zasshi; 1993 Mar; 68(2):237-50. PubMed ID: 8509066
[TBL] [Abstract][Full Text] [Related]
12. Nuclear topography and expression of the BCR/ABL fusion gene and its protein level influenced by cell differentiation and RNA interference.
Bártová E; Harnicarová A; Pacherník J; Kozubek S
Leuk Res; 2005 Aug; 29(8):901-13. PubMed ID: 15978941
[TBL] [Abstract][Full Text] [Related]
13. Influence of BCR/ABL fusion proteins on the course of Ph leukemias.
Telegeev GD; Dubrovska AN; Dybkov MV; Maliuta SS
Acta Biochim Pol; 2004; 51(3):845-9. PubMed ID: 15448745
[TBL] [Abstract][Full Text] [Related]
14. BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia.
Deininger MW; Vieira S; Mendiola R; Schultheis B; Goldman JM; Melo JV
Cancer Res; 2000 Apr; 60(7):2049-55. PubMed ID: 10766197
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction.
Mahon FX; Ripoche J; Pigeonnier V; Jazwiec B; Pigneux A; Moreau JF; Reiffers J
Exp Hematol; 1995 Dec; 23(14):1606-11. PubMed ID: 8542954
[TBL] [Abstract][Full Text] [Related]
16. High-resolution analysis of acquired genomic imbalances in bone marrow samples from chronic myeloid leukemia patients by use of multiple short DNA probes.
Reid AG; Tarpey PS; Nacheva EP
Genes Chromosomes Cancer; 2003 Jul; 37(3):282-90. PubMed ID: 12759926
[TBL] [Abstract][Full Text] [Related]
17. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
[TBL] [Abstract][Full Text] [Related]
18. Establishment and molecular characterization of a novel leukemic cell line with Philadelphia chromosome expressing p230 BCR/ABL fusion protein.
Wada H; Mizutani S; Nishimura J; Usuki Y; Kohsaki M; Komai M; Kaneko H; Sakamoto S; Delia D; Kanamaru A
Cancer Res; 1995 Jul; 55(14):3192-6. PubMed ID: 7606740
[TBL] [Abstract][Full Text] [Related]
19. Chromatin alterations surrounding the BCR/ABL fusion gene in K562 cells.
Schaefer-Rego KE; Leibowitz D; Mears JG
Oncogene; 1990 Nov; 5(11):1669-73. PubMed ID: 2267134
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.
Huang M; Dorsey JF; Epling-Burnette PK; Nimmanapalli R; Landowski TH; Mora LB; Niu G; Sinibaldi D; Bai F; Kraker A; Yu H; Moscinski L; Wei S; Djeu J; Dalton WS; Bhalla K; Loughran TP; Wu J; Jove R
Oncogene; 2002 Dec; 21(57):8804-16. PubMed ID: 12483533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
